National Institute for Health and Care Excellence gives green light to Darzalex® (daratumumab) with lenalidomide and dexamethasone for patients with n
Daratumumab combination is recommended for use within the NHS in England and Wales for treating adults with newly diagnosed multiple myeloma where a stem cell transplant is unsuitableEligible patients throughout England and Wales can now access alternative combination treatment option which has been shown to delay d...
Source: pharmiweb.com
